The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group.
The efficacy and safety of a combination of Persantine and aspirin, of aspirin alone and of a placebo as a regimen for preventing reinfarction were compared in 2026 patients who had recovered from a documented acute myocardial infarction (MI) that had occurred 8 weeks to 5 years previously. Baseline variables were comparable, and almost all surviving patients were treated for 3 years. There was a trend toward improved survival rates both for the combination and single drug compared with placebo. Coronary incidence was significantly lower in the combination group compared with placebo at each 4-month interval during the first 24 months of treatment, whereas significant reductions in the aspirin group occurred only at 8 and 24 months. Gastric and renal side effects were more common in the treated groups. To confirm the above results and the findings that the group of patients enrolled within 6 months of last MI had the largest reduction in mortality in the combination group, another study has been designed to compare the combination with a placebo in a large group of patients.
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001806:Blood Urea Nitrogen; D002561:Cerebrovascular Disorders / Q000175:diagnosis; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000401:mortality; D003404:Creatinine / Q000097:blood; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000175:diagnosis; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010919:Placebos; D011897:Random Allocation; D014527:Uric Acid / Q000097:blood
D010919:Placebos; D014527:Uric Acid; D004176:Dipyridamole; D003404:Creatinine; D001241:Aspirin